FOXO4-DRI

Buy FOXO4-DRI Research Peptide — Cellular Senescence Research Compound

Researchers looking to buy FOXO4-DRI research peptide for laboratory study will find this synthetic proline-rich peptide one of the more extensively investigated compounds in the emerging senolytic research category. FOXO4-DRI (FOXO4 D-Retro-Inverso) is a modified peptide derived from the FOXO4 transcription factor, designed to disrupt the interaction between FOXO4 and p53 in cellular senescence research models. The compound was originally developed and characterized by Dr. Peter de Keizer and colleagues, and published research in 2017 in Cell established FOXO4-DRI as a foundational research tool for investigating senescent cell biology in preclinical models.

Mechanism of Action

FOXO4-DRI has been investigated in published research for activity across several biological pathways, including:

• FOXO4-p53 interaction disruption — the peptide is designed to interfere with the interaction between FOXO4 and p53 in senescent cells, where this interaction is documented in research to sequester p53 in the nucleus
• p53-mediated apoptosis research — following disruption of the FOXO4-p53 interaction, research documents p53 release and downstream apoptotic pathway activation in senescent cells
• Senescent cell clearance research — preclinical investigations into selective clearance of senescent cells in cell culture and animal research models
• D-Retro-Inverso peptide chemistry — research on the enhanced stability and resistance to enzymatic degradation associated with the D-amino acid substitution and reversed peptide sequence
• Cellular senescence pathway research — investigations into the senescence-associated secretory phenotype (SASP) and related inflammatory pathway research

FOXO4-DRI is distinguished in research literature as one of the first designed peptide senolytics — specifically engineered as a research tool to selectively affect senescent cells while leaving non-senescent cells relatively unaffected in preclinical research models. This selectivity profile has made it a foundational reference compound in the broader senolytic research category.

Research Applications

FOXO4-DRI is used in research contexts including:

• Cellular senescence and senescent cell biology research
• FOXO4-p53 interaction pharmacology and receptor research
• Comparative senolytic research alongside other candidate senolytic compounds
• Preclinical models of age-related cellular decline
• Research on the senescence-associated secretory phenotype (SASP)
• D-Retro-Inverso peptide chemistry research

Product Specifications

• Compound: FOXO4-DRI (FOXO4 D-Retro-Inverso)
• Form: Lyophilized white powder
• Purity: ≥98% (verified by HPLC and mass spectrometry)
• Sequence: Contains D-amino acid substitutions and reversed peptide sequence for enhanced stability
• Available sizes: 10mg
• Third-party tested: Certificate of Analysis available on request, including verification of stereochemistry

Reconstitution & Storage

Lyophilized FOXO4-DRI should be stored at -20°C for long-term stability and protected from light. FOXO4-DRI is a proline-rich peptide with limited water solubility — reconstitution typically requires a small volume of DMSO (dimethyl sulfoxide) as a solubilizing agent before dilution with bacteriostatic water or research buffer, per published research protocols. Once reconstituted, the solution should be refrigerated at 2–8°C and used within the timeframe indicated on the product COA. Avoid repeated freeze-thaw cycles, as they can degrade peptide integrity.

Researchers should consult published literature for reconstitution buffer recommendations specific to their research model and downstream application.

Shipping & Handling

All orders are shipped with temperature-controlled packaging to preserve peptide integrity. Domestic orders typically arrive within 2–4 business days. Tracking is provided on every order.

Important Disclaimer

This product is sold strictly for laboratory research and in-vitro use only. It is not intended for human or animal consumption, diagnostic use, therapeutic use, longevity intervention, anti-aging application, or any form of clinical, medical, or personal application. By purchasing, you confirm that you are a qualified researcher or affiliated with a licensed research institution and that this product will be handled in accordance with all applicable laws and safety standards.

FOXO4-DRI has not undergone completed human clinical trials and is not approved by the FDA or any regulatory authority for any use. Published research on this compound is limited to preclinical animal and cell-based models. This product is not a substitute for any prescribed medication.